DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES

Inimmune正在开发第二代合成as01样佐剂系统（称为SAS），通过与我们的新型全合成TLR4激动剂ni -2002合作，与半合成皂素合作用于疫苗。临床前，SAS与分离的流感抗原配对时表现出优异的抗体和t细胞免疫反应。这种多功能疫苗佐剂有望显著增强对病毒和细菌疫苗的免疫反应，同时表现出良好的安全性。根据该合同，Inimmune将与其分包伙伴合作，优化、扩大和生产cGMP SAS，努力推进其IND申请。

Inimmune is developing a second generation synthetic AS01-like adjuvant system (termed SAS), by partnering our novel fully synthetic TLR4 agonist INI-2002, with a semi-synthetic saponin for use in vaccines. Pre-clinically, SAS has demonstrated excellent antibody and T-cell immune responses when paired with a split flu antigen. This versatile vaccine adjuvant is expected to provide a significant enhancement to the immune response to both viral and bacterial vaccines while exhibiting a favorable safety profile. Under this contract, Inimmune, in collaboration with its subcontracting partners, will optimize, scale-up, and produce cGMP SAS in an effort to advance it to an IND submission.